Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Prostate Cancer and Prostatic Diseases
Nieves Martinez ChanzaChristopher J Sweeney

Abstract

The appropriate management of localized or metastatic hormone-sensitive prostate cancer (HSPC) patients harboring tumor BRCA mutations (tBRCAm) is not well-characterized. We sought to evaluate the prevalence and clinical outcomes of patients with tBRCAm and localized or de novo metastatic HSPC. We performed a multicenter, international, retrospective cohort study of localized (cohort 1) and de novo metastatic (cohort 2) HSPC patients who underwent tumor BRCA1 and BRCA2 sequencing from 2013 to 2019. Primary endpoints included event-free survival (EFS) and metastases-free survival (MFS) for cohort 1, and time to castration-resistant prostate cancer (TTCRPC) and overall survival (OS) for cohort 2. Kaplan-Meier method and Cox regression models estimated the association of endpoints with tBRCA status. Of 399 identified patients with localized and de novo metastatic HSPC who underwent tumor BRCA1 and BRCA2 sequencing, 3.1% (8/258) patients of cohort 1 and 10.6% (15/141) patients of cohort 2 harbored tBRCAm. The median follow-up was 33 and 36 months, respectively. In cohort 1, median EFS was 18.1 vs. 57 months (p = 0.28) and MFS was 37 vs. 153.4 months (p = 0.08) for patients with tBRCAm compared to patients with no tBRCAm. In cohort ...Continue Reading

References

May 23, 2015·Cell·Dan RobinsonArul M Chinnaiyan
Aug 6, 2015·The New England Journal of Medicine·Christopher J SweeneyRobert S DiPaola
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Nov 7, 2015·Cell·UNKNOWN Cancer Genome Atlas Research Network
Feb 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group 3
Jun 6, 2017·The New England Journal of Medicine·Karim FizaziUNKNOWN LATITUDE Investigators
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators
Apr 4, 2018·Nature Genetics·Joshua ArmeniaEliezer M Van Allen
Jun 4, 2019·The New England Journal of Medicine·Ian D DavisUNKNOWN ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Sep 10, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J VanderWeeleMaha Hussain
Mar 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Konrad H StopsackWassim Abida
Apr 29, 2020·The New England Journal of Medicine·Johann de BonoMaha Hussain
Feb 6, 2021·Journal of the National Comprehensive Cancer Network : JNCCN·Edward SchaefferDeborah A Freedman-Cass

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.